Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Procainamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.62 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.62 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 0.97 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.97 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Procainamide SCHEMBL40758 | 0.98 | BLM (1.00) | ALDH1A1LMNATSHRSLC22A2SLC22A1 | |
| Procainamide SCHEMBL28944214 | 0.98 | ALDH1A1 (0.97) | ALDH1A1LMNATSHRSLC22A2SLC22A1 | |
| Procainamide SCHEMBL9614531 | 0.98 | BLM (1.00) | ALDH1A1LMNATSHRSLC22A2SLC22A1 | |
| Procainamide SCHEMBL9618624 | 0.97 | BLM (0.97) | ALDH1A1LMNATSHRSLC22A2SLC22A1 | |
| Procainamide SCHEMBL341750 | 0.97 | ALDH1A1 (0.94) | ALDH1A1LMNATSHRSLC22A2SLC22A1 | |
| Procainamide SCHEMBL23270847 | 0.97 | BLM (0.97) | ALDH1A1LMNATSHRSLC22A2SLC22A1 | |
| Procainamide SCHEMBL9437783 | 0.97 | BLM (0.97) | ALDH1A1LMNATSHRSLC22A2SLC22A1 | |
| Procainamide SCHEMBL5443536 | 0.97 | BLM (0.97) | ALDH1A1LMNATSHRSLC22A2SLC22A1 | |
| Procainamide SCHEMBL10717171 | 0.97 | BLM (0.97) | ALDH1A1LMNATSHRSLC22A2SLC22A1 | |
| Procainamide SCHEMBL9592794 | 0.97 | BLM (0.97) | ALDH1A1LMNATSHRSLC22A2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 19802 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| US-12637498-B2 | PDLIM2 as a biomarker for cancer and as an anti-cancer treatment target | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2026-05-26 | — | — | US | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-20260097012-A1 | COMPOSITIONS AND METHODS FOR TREATING GRAFT-RELATED ARRHYTHMIA | BLUEROCK THERAPEUTICS LP (US) | 2026-04-09 | — | — | US | claimed |
| US-12590970-B2 | Use of amino acids to enhance signal in mass spectral analyses | REGENERON PHARMACEUTICALS, INC. (US) | 2026-03-31 | — | — | US | claimed |
| EP-4691556-A2 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | H. Lundbeck A/S (DK) | 2026-02-11 | — | — | EP | claimed |
| US-20250387389-A1 | METHODS OF TREATING DISEASE WITH LEVOKETOCONAZOLE | XERIS PHARMACEUTICALS, INC. (US) | 2025-12-25 | — | — | US | claimed |
| US-12474326-B2 | Treatment methods having reduced drug-related toxicity and methods of identifying the likelihood of patient harm from prescribed medications | TABULA RASA HEALTHCARE, INC. (US) | 2025-11-18 | — | — | US | claimed |
| US-20250332291-A1 | MONOCLONAL ANTIBODIES FOR TARGETING THE CARDIAC CONDUCTION SYSTEM | UNIV LELAND STANFORD JUNIOR (US) | 2025-10-30 | — | — | US | claimed |
| US-4420568-A | DETERMINING LIGANDS IN SAMPLE | ABBOTT LABORATORIES (US) | 1983-12-13 | — | — | US | claimed |
| US-4404366-A | ENZYME CLEAVABLE GLYCOSIDIC LINKAGE | MILES LABORATORIES, INC. (US) | 1983-09-13 | — | — | US | claimed |
| US-4389393-A | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose | FOREST LABORATORIES, INC. (US) | 1983-06-21 | — | — | US | claimed |
| US-4369172-A | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose | FOREST LABORATORIES INC. (US) | 1983-01-18 | — | — | US | claimed |
| EP-0044441-A1 | Monoclonal antibodies to drugs, methods for their production and somatic cell hybridomas secreting them | MILES LABORATORIES, INC. (US) | 1982-01-27 | — | — | EP | claimed |
| US-4279992-A | Specific binding assay employing an enzyme-cleavable substrate as label | MILES LABORATORIES, INC. (US) | 1981-07-21 | — | — | US | claimed |
| US-4252786-A | POLYVINYLPYRROLIDONE WITH CARBOXYVINYL HYDROPHILIC POLYMER, INSOLUBLE BUT RUPTURABLE FILM | E. R. SQUIBB & SONS, INC. (US) | 1981-02-24 | — | — | US | claimed |
| US-4235969-A | IMMUNOASSAYS FOR DETERMINATION OF BENZAMIDES OF N,N-DIALKYLETHYLENEAMINES | SYVA COMPANY (US) | 1980-11-25 | — | — | US | claimed |
| US-4036227-A | Osmotic releasing device having a plurality of release rate patterns | ALZA CORPORATION (US) | 1977-07-19 | — | — | US | claimed |
| US-4014334-A | Laminated osmotic system for dispensing beneficial agent | ALZA CORPORATION (US) | 1977-03-29 | — | — | US | claimed |